Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03390790
Other study ID # 1112951-1
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 25, 2018
Est. completion date March 29, 2019

Study information

Verified date July 2019
Source Atlantic Health System
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Urodynamic testing can be associated with mild discomfort, particularly at the time of insertion, repositioning, and removal of the bladder catheter (a tube inserted into the bladder via the urethra). Few studies have investigated ways to improve patient comfort during this procedure. In this study, the investigators want to see if applying external lidocaine (a numbing gel) prior to the procedure can help to minimize patient discomfort.


Description:

Urodynamic testing can be associated with mild discomfort, particularly at the time of insertion, repositioning, and removal of the bladder catheter (a tube inserted into the bladder via the urethra). Few studies have investigated ways to improve patient comfort during this procedure. In this study, the investigators want to see if applying lidocaine (a numbing gel) prior to the procedure can help to minimize patient discomfort.

Participation in this study will involve only 1 clinic visit (for urodynamic testing), plus 2 phone calls to ask participants about pain (1 at 4-6 hours after testing; and 1 at 24 hours after testing). Additionally, the investigators will record any adverse effects (such as an allergic reaction to the gel or new irritation/pain) that happen within 2 weeks after testing.

Participants will be randomly assigned to receive either lidocaine gel or placebo gel for their urodynamic testing. The placebo gel will be a standard lubricant gel, meaning that it contains no active drug. The assigned study regimen will be chosen by chance, like flipping a coin. Participants will have an equal (50/50) chance of being given either study regimen. Neither the participant nor the study doctor or nurse practitioner will know which study regimen the participant is getting. Additionally, a member of the study team will ask participants about their pain level before and after the testing. The rest of the urodynamic testing procedure will take place exactly as it would if the participant was not in this research study.


Recruitment information / eligibility

Status Completed
Enrollment 134
Est. completion date March 29, 2019
Est. primary completion date March 29, 2019
Accepts healthy volunteers No
Gender Female
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria:

• All female patients between the ages of 40-80 undergoing urodynamic testing.

Exclusion Criteria:

- Urinary tract infection or symptoms of infection at time of procedure or within past 2 weeks

- History of urinary retention

- Known or suggested history of urethral syndrome or painful bladder syndrome

- Prior anti-incontinence surgery

- Prior pelvic surgery with placement of transvaginal mesh

- Known urethral or bladder anomaly including urethral diverticulum or congenital anomalies of the bladder or urethra

- History of genital herpes outbreak within the past 3 months

- Defects in mucosal surfaces including periurethral or vaginal abrasions, ulcerations, or lacerations

- Neurologic disease affecting urethral sensation

- Chronic pelvic pain

- Contraindication or allergy to topical anesthetic

- Pregnancy

- Syncopal episode during preparation for or execution of uroflowometry

Study Design


Intervention

Drug:
Lidocaine gel 2%
If assigned to this intervention via randomization, participants will receive lidocaine (numbing) gel prior to their urodynamics procedure.
Other:
Standard lubricant gel
If assigned to this intervention via randomization, participants will receive standard lubricant gel prior to their urodynamics procedure.

Locations

Country Name City State
United States Atlantic Health System Morristown New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Atlantic Health System

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The change in patient visual analog pain score (vaginal area only) from before procedure to 4-6 hours after urodynamic testing Participants will rate their pain according to a visual analog pain scale from 0 (no pain) to 100 (worst pain imaginable). Baseline and 4-6 hours post procedure.
Secondary Change in patient visual analog pain score (vaginal area only) from before procedure to 24 hours after urodynamic testing. Participants will rate their pain according to a visual analog pain scale from 0 (no pain) to 100 (worst pain imaginable). Baseline and 24 hours post procedure.
Secondary Patient visual analog pain score (vaginal area only) before procedure, at conclusion of all procedure-related activities, 4-6 hours after procedure, and 24 hours after procedure. Participants will rate their pain according to a visual analog pain scale from 0 (no pain) to 100 (worst pain imaginable). Baseline and 24 hours post procedure.
Secondary To assess voiding difficulties and other adverse events immediately after urodynamic testing, at 4-6 hours, 24 hours, and two weeks after urodynamic testing. Participants will receive a phone call at 4-6 hours and 24 hours after urodynamic testing. Any study participant-initiated complaints of voiding difficulties within two weeks of the procedure will be documented and addressed. Baseline and 2 weeks post-procedure.
Secondary Urodynamic findings Standard urodynamics findings will be analyzed. At time of procedure.
Secondary Procedure time Procedure time will be recorded for all subjects. At time of procedure.
See also
  Status Clinical Trial Phase
Recruiting NCT05534412 - A Practice-Based Intervention To Improve Care for a Diverse Population Of Women With Urinary Incontinence N/A
Recruiting NCT05515198 - Improving Care for Women With Urinary Incontinence (EMPOWER) N/A
Completed NCT04071301 - Collection of Real-life Measurement Data for TENA SmartCare Change Indicator in Subjects With Urinary Incontinence N/A
Completed NCT03623880 - Enhancing Behavioral Treatment for Women With Pelvic Floor Disorders N/A
Recruiting NCT05880862 - Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls Early Phase 1
Recruiting NCT04159467 - Effect of Pelvic Floor Muscle Training on Urinary Incontinence Reports in Obese Women Undergoing a Low Calorie Diet N/A
Completed NCT05485922 - Performance of a Single-use Intermittent Micro-hole Zone Catheter N/A
Completed NCT06268782 - The Effectiveness of an Online Exercise Program on Well-being of Postpartum Women N/A
Not yet recruiting NCT03027986 - Evaluation of a Postural Rehabilitation Program Based on Sensory-motor Control in Men With Urinary Incontinence After Prostatectomy N/A
Recruiting NCT02490917 - ACT™ Balloons Versus Artificial Urinary Sphincter (AMS800™) for the Treatment of Female Stress Urinary Incontinence N/A
Enrolling by invitation NCT02529371 - Pre-Marketing Feasibility Evaluation of the UriCap-RM - Urine Collection in Hospitalized Male Patients N/A
Enrolling by invitation NCT02530372 - Feasibility of the UriCap-F for Urine Collection in Hospitalized Women N/A
Completed NCT02549729 - Effect of the Pelvic Floor Training in Postmenopausal Women With or Without Hormonal Therapy N/A
Completed NCT02600676 - Transcutaneous Electric Nerve Stimulation (TENS) in Children With Enuresis N/A
Completed NCT02338726 - Pelvic Floor Symptoms and Quality of Life in Elderly Women - a Population-based Pilot Study N/A
Completed NCT02368262 - Prevalence of Incontinence and Risk Factors in Children With Cerebral Palsy N/A
Completed NCT02239796 - Feasibility Controlled Trial of Tibial Nerve Stimulation for Stroke Related Urinary Incontinence N/A
Completed NCT01942681 - Female Patients With Signs of uRgE and Stress Urinary Incontinence Study of Propiverine Hydrochloride N/A
Recruiting NCT01804153 - Stem Cells Tratment for the Local Feminine Stress Urinary Incontinence Treatment (HULPURO) Phase 1/Phase 2
Completed NCT01520948 - Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease Phase 3